Medicare Now Covers GLP-1 Weight Loss Drugs: What You Need to Know

For decades, Medicare explicitly excluded coverage of medications prescribed for weight loss. This exclusion was established in 2003 and remained in place even as the obesity epidemic worsened and effective new treatments emerged. The legislative change was driven by several factors: Growing evidence that obesity is a chronic disease requiring medical treatment, not just lifestyle changes. The FDA's expanded approval of GLP-1 medications for cardiovascular risk reduction provided additional medical justification. Bipartisan congressional support recognizing that treating obesity reduces downstream Medicare costs for diabetes, heart disease, and joint replacements. The Congressional Budget Office estimated that covering anti-obesity medications could save Medicare billions over the next decade by reducing obesity-related hospitalizations and procedures.

Medicare coverage for GLP-1 weight loss medications applies to beneficiaries who meet specific criteria:

Medicare Part D plans are required to cover at least one medication in the GLP-1 anti-obesity category. Most plans now cover: Wegovy (semaglutide 2.4mg): The most widely covered option, with FDA approval specifically for chronic weight management. Zepbound (tirzepatide): Eli Lilly's dual GIP/GLP-1 receptor agonist, approved for weight loss. Coverage is growing but may require step therapy (trying Wegovy first). Saxenda (liraglutide 3mg): An older GLP-1 option that some plans cover as a lower-cost alternative. Coverage does not typically extend to compounded versions of these medications. Only FDA-approved brand-name products are eligible for Medicare reimbursement.

Your costs depend on your specific Medicare Part D plan, but here's the general picture: Initial deductible: Most Part D plans have a deductible ($545 in 2026) that must be met before coverage kicks in. Copay/coinsurance: After the deductible, you'll typically pay 25% of the drug cost during the initial coverage phase. For Wegovy at ~$1,300/month, that's roughly $325/month. Coverage gap: Once you and your plan have spent a combined $5,030 on drugs, you enter the coverage gap where costs may increase. Catastrophic coverage: After $8,000 in out-of-pocket spending, catastrophic coverage kicks in and your costs drop to $0 or small copays. Manufacturer programs: Both Novo Nordisk and Eli Lilly offer copay assistance programs that can significantly reduce your out-of-pocket costs, even with Medicare.

If you're a Medicare beneficiary interested in GLP-1 medications for weight loss: Step 1: Talk to your doctor about whether you meet the eligibility criteria. Bring documentation of your BMI and any weight-related health conditions. Step 2: Your provider will submit a prior authorization to your Part D plan. This typically requires medical records showing BMI, comorbidities, and previous weight loss attempts. Step 3: If approved, fill your prescription at a Part D network pharmacy. Mail-order pharmacies often offer better pricing. Step 4: Some plans require periodic check-ins or documentation of continued medical necessity. Keep your follow-up appointments and track your progress. If your prior authorization is denied, you have the right to appeal. Many initial denials are overturned on appeal with additional documentation from your provider.

Medicare coverage has significantly impacted the GLP-1 market: Demand surge: Manufacturers have reported increased demand, though supply has largely kept pace thanks to manufacturing expansions. Price negotiations: Medicare's ability to negotiate drug prices under the Inflation Reduction Act may eventually bring GLP-1 costs down for all payers. Provider expansion: More primary care physicians are now prescribing GLP-1 medications, as Medicare coverage has legitimized their use for weight management. Telehealth access: Medicare-accepting telehealth platforms have expanded their GLP-1 programs, making it easier for seniors to access treatment remotely.